ClassID:

21491

A61K49/143 - CPC Classification

Classification description:

Preparations for testing; Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier; Organic compounds; Peptides, e.g. proteins the protein being an albumin, e.g. HSA, BSA, ovalbumin

Recent Application in this class:
#1
20260108641
2026-04-23

PHYTIC ACID-BASED TERNARY COMPLEX BIOMIMETIC NANOMATERIAL, AND PREPARATION METHOD AND USE THEREOF

#2
20240228524
2024-07-11

IRON(III) MACROCYCLIC COMPLEXES WITH MIXED HYROXYL PENDANTS AS MRI CONTRAST AGENTS

#3
20240082434
2024-03-14

CONTRAST AGENTS, METHODS FOR PREPARING CONTRAST AGENTS, AND METHODS OF IMAGING

#4
20230405115
2023-12-21

COMBINATION THERAPY OF MDNA55 AND A VASCULAR ENDOTHELIAL GROWTH FACTOR A (VEGF-A)

#5
20230057249
2023-02-23

TARGETED PROTEIN CONTRAST AGENTS, METHODS OF MAKING, AND USES THEREOF

#6
20220259244
2022-08-18

COMPOUNDS FOR USE AS IRON(III) MRI CONTRAST AGENTS

#7
20210038746
2021-02-11

Targeted protein contrast agents, methods of making, and uses thereof

#8
20210038745
2021-02-11

Contrast agents, methods for preparing contrast agents, and methods of imaging

#9
20200397925
2020-12-24

Targeted protein contrast agents, methods of making, and uses thereof

#10
20200323897
2020-10-15

METHODS FOR DISTRIBUTING AGENTS TO AREAS OF BRAIN

#11
20200079806
2020-03-12

Compounds for use as iron(III) MRI contrast agents

#12
20180327387
2018-11-15

Cyanine compounds

#13
20180280544
2018-10-04

Targeted protein contrast agents, methods of making, and uses thereof

#14
20180250426
2018-09-06

Contrast agents, methods for preparing contrast agents, and methods of imaging

#15
20170114038
2017-04-27

CYANINE COMPOUNDS

#16
20160176852
2016-06-23

Cyanine compounds

#17
20150283272
2015-10-08

Dual mode gadolinium nanoparticle contrast agents

#18
20130190605
2013-07-25

Methods and compositions for objectively characterizing medical images

#19
20120087869
2012-04-12

Methods for distributing agents to areas of brain

#20
20110142762
2011-06-16

Conjugates for medical imaging comprising carrier, targeting moiety and a contrast agent

#21
20110097742
2011-04-28

CONTRAST AGENTS, METHODS FOR PREPARING CONTRAST AGENTS, AND METHODS OF IMAGING

#22
20100209353
2010-08-19

TUMOR TARGETING PROTEIN CONJUGATE AND A METHOD FOR PREPARING THE SAME

#23
20100163778
2010-07-01

Simple method for introducing magnetic particles into a polymer

#24
20100015044
2010-01-21

Methods and compositions for diagnosis of iga-and igm-mediated kidney diseases

#25
20090197316
2009-08-06

Process for preparing particles of proteinaceous material

#26
20070122346
2007-05-31

Conjugated macromolecules

#27
20070014725
2007-01-18

Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy

#28
20070009442
2007-01-11

Macrocyclic metal complexes and their use for the production of conjugates with biomolecules

#29
20070003484
2007-01-04

Hydroxypyridinone derivatives, metal complexes thereof and the use thereof for preparing conjugates with biomolecules

#30
20060292079
2006-12-28

Conjugates of hydroxypyridinone derivative metal complexes with biomolecules and their use for MRI diagnosis

#31
20060171892
2006-08-03

Conjugates for medical imaging comprising carrier, targetting moiety and a contrast agent

#32
20060104902
2006-05-18

Method of preselection patients for anti-VEGF, anti-HIF-1 or anti-thioredoxin therapy

#33
20050013778
2005-01-20

Methods and compositions for predicting the response to a therapeutic regimen in a subject having a disease associated with cell death